Navigation Links
Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
Date:6/8/2011

the age of 50. According to the National Parkinson Foundation, 1 million Americans currently have PD, and an estimated 50,000 to 60,000 new cases are diagnosed each year in the United States. Standard therapy for PD often involves use of levodopa, a drug which stimulates production of dopamine. Unfortunately, many patients develop complications from this and other medications, or they can fail to be effective.  An alternative treatment is electrical deep brain stimulation, which requires the implantation of permanent medical devices in the brain.

About Neurologix

Neurologix, Inc. (OTCBB:NRGX) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system. Neurologix's therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. The Company's current programs address such conditions as Parkinson's disease, epilepsy, depression and Huntington's disease, all of which are large markets not adequately served by current therapeutic options. For more information, please visit the Neurologix website at http://www.neurologix.net.

Cautionary Statement Regarding Forward-Looking Statements

This news release includes certain statements of the Company that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently avai
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. Neurologix Reports Third Quarter 2010 Financial Results
4. Neurologix Completes Additional $7 Million Financing
5. Neurologix Announces First Quarter 2011 Financial Results
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 ... today announced that it has taken an exclusive worldwide ... FScan Ltd, a Durham University ... Pharma will pay an upfront fee, development and commercial ... Pharma has also taken an option for additional exclusive ...
(Date:7/28/2014)... Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH ), today announced ... June 30, 2014. Net loss for the ... to $8.3 million for the same period in 2013. The ... decrease in interest expense in the current period.  ... 2014 was $15.2 million, compared with net loss of $15.9 ...
(Date:7/28/2014)... YORK , July 28, 2014 Reportbuyer.com ... Global Bone Densitometers Market 2014-2018 ... A bone densitometry scan is a special type of ... a bone. It is used primarily to detect osteopenia ... low and the risk of fractures is high. The ...
Breaking Medicine Technology:Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 2Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3Global Bone Densitometers Market 2014-2018 4Global Bone Densitometers Market 2014-2018 5
... MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® ... Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc ... market adoption of Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual ... announcement of full-year 2010 financial results. ...
... Feb. 22, 2011 Prasco Laboratories ... supply agreement with Shire US Manufacturing, Inc. for ... Prasco, LLC is prepared to market the authorized ... Shire,s request, immediately upon any entrance into the ...
Cached Medicine Technology:MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010 2MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010 3
(Date:7/29/2014)... New Haven, CT (PRWEB) July 29, 2014 ... head up its Client Services Operation. , Christina Upton, ... been named Director of Client Services responsible for managing ... , Client Services is at the center of all ... the most well-known brands in the world . The ...
(Date:7/29/2014)... 1WorldSync announces B. Braun Melsungen AG, ... utilize the Global Data Synchronization Network™ (GDSN®) standard ... product information with the U.S. Food and Drug ... global supply chain. Holger Clobes, Head of Global ... Braun serves customers in 61 countries, among others ...
(Date:7/29/2014)... Collierville, TN (PRWEB) July 29, 2014 ... to the reimbursement model of all hospitals. Studies show ... tsunami.[1] One simple, easy, low cost tool that ... organizational performance by 20 to 25%. , Their secret? ... to one anther at the end of an operational ...
(Date:7/29/2014)... Doheny HealthDay Reporter , MONDAY, ... risk of cardiovascular disease may be able to take hormone ... harming their hearts, according to a new study. Previous ... replacement therapy had harmful effects on the heart. But, many ... treatments, and much further past menopause. In this ...
(Date:7/29/2014)... San Francisco, California (PRWEB) July 29, 2014 ... to reach USD 9,542.3 million by 2020, growing at ... according to a new study by Grand View Research, ... acceptance of these devices by the geriatric population, along ... are some of the major drivers of this market. ...
Breaking Medicine News(10 mins):Health News:CRN International Names New Director to Lead Client Services Department 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 2Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 3Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 4Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 5Health News:Audiology Devices Market Analysis by Product (Cochlear Implants, Bone Anchored Hearing Aids, Hearing Aids, Audiometers) Expected to Reach USD 9,542.3 Million by 2020 6
... Human Services reported that very little precautionary measures can be ... flu) // . The infection in humans is actually caused ... ,Hence to prevent the global pandemic it has issued various ... a global pandemic. The government says that as such ...
... Guarraci, an assistance professor of psychology at south-western university and ... has a greater effect on the sexual behaviour of female ... and is among the first to determine the effects of ... also probes into the relationship between caffeine and sex. ...
... press that all the medical expenditures of pregnant women will be ... ,This plan is introduced mainly to ensure proper ... six months this plan will add $5 million to the annual ... the amount of expenditure of the rural women by $18. The ...
... of lives ever year. The need the organ, kidney is on ... ,Of all the organ transplantations done, kidney transplantation accounts ... sudden fall in the number of people who come forward to ... of the patients to undergo kidney transplants has widened to more ...
... Science Museum in London has found a unique way to help ... people the much-needed dose of light // . ,The ... of dark winter days. ,Up to 500,000 people, a ... seasonal affective disorder. SAD is more common in the northern ...
... an 8% increase in its share, following approval of Vivagel ... of HIV. // The company even signed a $20 ... and Infectious Diseases, an integral part of the National Institute ... for the prevention of HIV infection. The FDA recognizes the ...
Cached Medicine News:Health News:Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission 2
The Advance revision knee system was designed to address the unpredictable nature of revision knee arthroplasty by providing a wide variety of implant and instrument options....
... CRA femoral component is intended for ... and varus/valgus ligament stability, yet require ... inadequate bone stock. The NexGen CRA ... PMMA precoat surface. This device is ...
... manufacturers focus attention on implant design, one ... Profix Total Knee System seeks to establish ... system and the tools to implant them. ... recognized for innovation in total knee instrumentation, ...
Cruciate retaining, posterior stabilized and constrained components....
Medicine Products: